Cost-effectiveness of preimplantation genetic testing for aneuploidies.

<bold>Objective: </bold>To evaluate the economical benefit of preimplantation genetic testing of aneuploidies (PGT-A) when applied in an extended culture and stringent elective single ET framework.<bold>Design: </bold>Theoretical cost-effectiveness study.<bold>Setting: </bold>Not applicable.<bold>Patients/animal(s): </bold>None.<bold>Intervention(s): </bold>Comparison of the cost-effectiveness between two IVF treatment strategies: serial transfer of all available blastocysts without genetic testing (first fresh transfer and subsequent frozen-thawed transfer); and systematic use of genetic testing (trophectoderm biopsy, freeze-all, and frozen-thawed transfers of euploid blastocysts). The costs considered for this analysis are based on regional public health system provider.<bold>Main Outcome Measure(s): </bold>Costs per live birth.<bold>Result(s): </bold>Cost-effectiveness profile of PGT-A improves with female age and number of available blastocysts. Sensitivity analyses varying the costs of ET, the costs of genetic analyses, the magnitude of the detrimental impact of PGT-A on live birth rate, and the crude live birth rates change to some extent the thresholds for effectiveness but generally confirm the notion that PGT-A can be economically advantageous in some specific subgroups.<bold>Conclusion(s): </bold>PGT-A can be cost-effective in specific clinical settings and population groups. Economic considerations deserve attention in the debate regarding the clinical utility of PGT-A. [ABSTRACT FROM AUTHOR]